ReviewCancers2019
Adjuvant Biophysical Therapies in Osteosarcoma.
Review in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Exploring gene biomarkers and targeted drugs for ferroptosis and cuproptosis in osteosarcoma: A bioinformatic approach.Environmental toxicology · 2025Article
- Iron oxide nanoparticles coated with bioactive materials: a viable theragnostic strategy to improve osteosarcoma treatment.Discover nano · 2025Review
- Dual-Function Biomaterials for Postoperative Osteosarcoma: Tumor Suppression and Bone Regeneration.Research (Washington, D.C.) · 2025Review
- Protective effect of low-intensity pulsed ultrasound on immune checkpoint inhibitor-related myocarditis via fine-tuning CD4Cancer immunology, immunotherapy : CII · 2024Article
- Low intensity pulsed ultrasound ameliorates Adriamycin-induced chronic renal injury by inhibiting ferroptosis.Redox report : communications in free radical research · 2023Article
- Article
- Hsa_circ_0001982 promotes the proliferation, invasion, and multidrug resistance of osteosarcoma cells.Journal of clinical laboratory analysis · 2022Article
- Article
- TRIP13 knockdown inhibits the proliferation, migration, invasion, and promotes apoptosis by suppressing PI3K/AKT signaling pathway in U2OS cells.Molecular biology reports · 2022Article
- Emerging role of m6A modification in osteogenesis of stem cells.Journal of bone and mineral metabolism · 2022Review
- Role of autophagy in drug resistance and regulation of osteosarcoma (Review).Molecular and clinical oncology · 2022Review
- Association of RDM1 with osteosarcoma progression via cell cycle and MEK/ERK signalling pathway regulation.Journal of cellular and molecular medicine · 2021Article
- RNF219/Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- Perspective Applications and Associated Challenges of Using Nanocellulose in Treating Bone-Related Diseases.Frontiers in bioengineering and biotechnology · 2021Review
- LINC00665 Facilitates the Malignant Processes of Osteosarcoma by Increasing the RAP1B Expression via Sponging miR-708 and miR-142-5p.Analytical cellular pathology (Amsterdam) · 2021Article
- Precise Diagnosis and Therapy of Bone Cancer Using Near-Infrared Lights.Frontiers in bioengineering and biotechnology · 2021Review
- Review on experimental study and clinical application of low-intensity pulsed ultrasound in inflammation.Quantitative imaging in medicine and surgery · 2021Review
- Effect of activation of the Akt/mTOR signaling pathway by EEF1A2 on the biological behavior of osteosarcoma.Annals of translational medicine · 2021Article
- MicroRNA-208a-3p promotes osteosarcoma progression via targeting PTEN.Experimental and therapeutic medicine · 2020Article
- Enhanced Internalization of Nanoparticles Following Ionizing Radiation Leads to Mitotic Catastrophe in MG-63 Human Osteosarcoma Cells.International journal of molecular sciences · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma (OS) is a primary bone sarcoma, manifesting as osteogenesis by malignant cells. Nowadays, patients' quality of life has been improved, however continuing high rates of limb amputation, pulmonary metastasis and drug toxicity, remain unresolved issues. Thus, effective osteosarcoma therapies are still required. Recently, the potentialities of biophysical treatments in osteosarcoma have been evaluated and seem to offer a promising future, thanks in this field as they are less invasive. Several approaches have been investigated such as hyperthermia (HT), high intensity focused ultrasound (HIFU), low intensity pulsed ultrasound (LIPUS) and sono- and photodynamic therapies (SDT, PDT). This review aims to summarize in vitro and in vivo studies and clinical trials employing biophysical stimuli in osteosarcoma treatment. The findings underscore how the technological development of biophysical therapies might represent an adjuvant role and, in some cases, alternative role to the surgery, radio and chemotherapy treatment of OS. Among them, the most promising are HIFU and HT, which are already employed in OS patient treatment, while LIPUS/SDT and PDT seem to be particularly interesting for their low toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.